EIF5B: A Potential Drug Target and Biomarker (G9669)
EIF5B: A Potential Drug Target and Biomarker
Eukaryotic translation initiation factor 5B (EIF5B) is a protein that plays a crucial role in the process of protein synthesis in eukaryotic cells. It is a key factor in the initiation of the translation of mRNAs, which are the templates for protein synthesis. EIF5B is a 21-kDa protein that consists of 115 amino acid residues. It is expressed in most eukaryotic cells and is involved in the initiation of protein synthesis from mRNAs.
EIF5B functions as a molecular chaperone, which means it helps to transport and guide mRNAs through the translation machinery. It does this by interacting with the ribosome, which is the protein complex that performs the actual translation of mRNAs. EIF5B is also involved in the regulation of the activity of the ribosome, which is essential for protein synthesis.
One of the unique features of EIF5B is its ability to interact with various types of mRNAs, including those that are associated with neurodegenerative diseases. This suggests that EIF5B may be a potential drug target for these diseases, as blocking its function may offer a new approach to treat these conditions.
EIF5B has also been shown to be involved in the regulation of cellular processes that are important for cancer development. It has been shown to play a role in the regulation of cell cycle progression, which is the process by which cells divide and grow. EIF5B has has also been shown to be involved in the regulation of apoptosis, which is the process by which cells die when they are no longer needed.
In addition to its role in the regulation of cell cycle progression and apoptosis, EIF5B has also been shown to be involved in the regulation of protein synthesis. It has been shown to interact with the ribosome and to regulate the activity of the ribosome. This suggests that EIF5B may be a potential biomarker for monitoring the effectiveness of drugs that are designed to inhibit its function.
EIF5B is also a potential drug target because of its ability to interact with other proteins that are involved in the development and progression of neurodegenerative diseases. For example, EIF5B has been shown to interact with the protein involved in the development of Alzheimer's disease, which is thought to be associated with the production of beta-amyloid plaques. This suggests that blocking EIF5B's function may be a potential approach to treating Alzheimer's disease.
In conclusion, EIF5B is a protein that plays a crucial role in the initiation of protein synthesis in eukaryotic cells. It is a potential drug target and biomarker for a variety of neurodegenerative diseases, including Alzheimer's disease. Further research is needed to fully understand the role of EIF5B in these conditions and to develop effective treatments.
Protein Name: Eukaryotic Translation Initiation Factor 5B
Functions: Plays a role in translation initiation. Translational GTPase that catalyzes the joining of the 40S and 60S subunits to form the 80S initiation complex with the initiator methionine-tRNA in the P-site base paired to the start codon. GTP binding and hydrolysis induces conformational changes in the enzyme that renders it active for productive interactions with the ribosome. The release of the enzyme after formation of the initiation complex is a prerequisite to form elongation-competent ribosomes
The "EIF5B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF5B comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
EIF6 | EIPR1 | ELAC1 | ELAC2 | ELANE | ELAPOR1 | ELAPOR2 | Elastase | ELAVL1 | ELAVL2 | ELAVL3 | ELAVL4 | ELDR | ELF1 | ELF2 | ELF2P4 | ELF3 | ELF3-AS1 | ELF4 | ELF5 | ELFN1 | ELFN1-AS1 | ELFN2 | ELK1 | ELK2AP | ELK3 | ELK4 | ELL | ELL2 | ELL2P1 | ELL3 | ELMO1 | ELMO2 | ELMO3 | ELMOD1 | ELMOD2 | ELMOD3 | ELN | ELOA | ELOA-AS1 | ELOA2 | ELOA3BP | ELOA3DP | ELOA3P | ELOB | ELOC | ELOF1 | Elongation Factor 1 Complex | Elongation of very long chain fatty acids protein | Elongin (SIII) complex | ELOVL1 | ELOVL2 | ELOVL2-AS1 | ELOVL3 | ELOVL4 | ELOVL5 | ELOVL6 | ELOVL7 | ELP1 | ELP2 | ELP3 | ELP4 | ELP5 | ELP6 | ELSPBP1 | EMB | EMBP1 | EMC1 | EMC1-AS1 | EMC10 | EMC2 | EMC3 | EMC3-AS1 | EMC4 | EMC6 | EMC7 | EMC8 | EMC9 | EMCN | EMD | EME1 | EME2 | EMG1 | EMID1 | EMILIN1 | EMILIN2 | EML1 | EML2 | EML2-AS1 | EML3 | EML4 | EML4-AS1 | EML5 | EML6 | EMP1 | EMP2 | EMP2P1 | EMP3 | EMSLR | EMSY
